Vanguard Group Inc. Buys 65,960 Shares of Palvella Therapeutics, Inc. $PVLA

Vanguard Group Inc. raised its stake in Palvella Therapeutics, Inc. (NASDAQ:PVLA) by 13.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 560,616 shares of the company’s stock after purchasing an additional 65,960 shares during the period. Vanguard Group Inc. owned 4.73% of Palvella Therapeutics worth $58,680,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in PVLA. First Light Asset Management LLC bought a new stake in Palvella Therapeutics in the 3rd quarter valued at about $33,949,000. Federated Hermes Inc. acquired a new stake in Palvella Therapeutics in the third quarter valued at approximately $21,255,000. Millennium Management LLC acquired a new stake in Palvella Therapeutics in the first quarter valued at approximately $7,553,000. Fred Alger Management LLC grew its stake in Palvella Therapeutics by 1,279.1% in the third quarter. Fred Alger Management LLC now owns 186,751 shares of the company’s stock valued at $11,707,000 after acquiring an additional 173,209 shares during the period. Finally, Balyasny Asset Management L.P. acquired a new stake in Palvella Therapeutics in the third quarter valued at approximately $10,440,000. 40.11% of the stock is owned by institutional investors.

Palvella Therapeutics Stock Performance

Shares of PVLA opened at $114.24 on Friday. The stock has a 50 day moving average price of $124.49 and a two-hundred day moving average price of $104.18. The firm has a market capitalization of $1.64 billion, a P/E ratio of -27.40 and a beta of -0.13. Palvella Therapeutics, Inc. has a 52 week low of $20.20 and a 52 week high of $151.18.

Palvella Therapeutics (NASDAQ:PVLA) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). On average, equities analysts forecast that Palvella Therapeutics, Inc. will post -5.43 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on PVLA shares. BTIG Research raised their price objective on Palvella Therapeutics from $192.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Stifel Nicolaus set a $250.00 price objective on Palvella Therapeutics in a research note on Tuesday, February 24th. TD Cowen reissued a “buy” rating on shares of Palvella Therapeutics in a research note on Monday, February 2nd. Truist Financial set a $210.00 price objective on Palvella Therapeutics in a research note on Tuesday, February 24th. Finally, Stephens started coverage on Palvella Therapeutics in a research note on Tuesday. They issued an “overweight” rating and a $220.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $199.53.

Insiders Place Their Bets

In related news, Director Elaine J. Heron acquired 2,400 shares of the firm’s stock in a transaction on Friday, February 27th. The stock was purchased at an average cost of $125.00 per share, with a total value of $300,000.00. Following the acquisition, the director owned 47,812 shares of the company’s stock, valued at approximately $5,976,500. This trade represents a 5.28% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director George M. Jenkins acquired 4,000 shares of the firm’s stock in a transaction on Friday, February 27th. The shares were bought at an average cost of $125.00 per share, with a total value of $500,000.00. Following the completion of the acquisition, the director directly owned 187,171 shares in the company, valued at approximately $23,396,375. This represents a 2.18% increase in their position. The SEC filing for this purchase provides additional information. Corporate insiders own 20.50% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.